Anaphylactic risk related to omalizumab, benralizumab, reslizumab, mepolizumab, and dupilumab

BACKGROUND: Monoclonal antibodies (mAbs) are novel, effective therapeutics for the treatment of inadequately controlled severe asthma. Knowledge of the anaphylaxis risks related to different mAbs is essential for their appropriate and safe administration. This study aimed to evaluate the association...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Lisha, Wang, Zixi, Cui, Le, Xu, Yingyang, Guan, Kai, Zhao, Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8175040/
https://www.ncbi.nlm.nih.gov/pubmed/34123366
http://dx.doi.org/10.1002/clt2.12038

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8175040/
https://www.ncbi.nlm.nih.gov/pubmed/34123366
http://dx.doi.org/10.1002/clt2.12038

Ejemplares similares